2026-01-04 - Analysis Report
Okay, let's break down the analysis of TG Therapeutics (TGTX) based on the information provided.

**0. Report in English**

**1. Return Rate vs. S&P 500 (VOO) & Alpha/Beta Analysis**

*   **TGTX Overview:** TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 69.10%
*   **VOO (S&P 500) Cumulative Return:** 91.00%
*   **Divergence:**
    *   Current: -21.9
    *   Relative Divergence: 15.5 (Meaning it's near the bottom of its divergence range from the S&P 500 historically)

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2016-2018  | -53.0% | 71.9% | -56.0% | 1.8  | 0.7    |
| 2017-2019  | 71.0%  | 71.9% | 54.0%  | 1.8  | 1.8    |
| 2018-2020  | 332.0% | 71.9% | 311.0% | 1.6  | 8.3    |
| 2019-2021  | 130.0% | 66.3% | 86.0%  | 1.6  | 3.0    |
| 2020-2022  | -86.0% | 90.0% | -84.0% | 1.9  | 1.9    |
| 2021-2023  | -315.0%| 89.7% | -316.0%| 2.4  | 2.7    |
| 2022-2024  | 57.0%  | 76.8% | 38.0%  | 2.3  | 4.8    |
| 2023-2025  | 67.0%  | 76.8% | 4.0%   | 1.1  | 4.7    |

**Analysis:**

*   **Underperformance:** TGTX has underperformed the S&P 500 in cumulative return.
*   **Volatility:** The Alpha/Beta analysis shows TGTX is significantly more volatile than the market (Beta consistently above 1). It exhibits periods of very strong outperformance (high positive Alpha) and significant underperformance (high negative Alpha).
*   **Risk:** High Maximum Drawdown (MDD) figures indicate substantial potential for losses.
*   **Recent Trend:** The most recent periods (2020-2022 and 2021-2023) show very large negative Alphas and CAGR, indicating a period of significant difficulty for the stock compared to the market. The last two periods (2022-2024 and 2023-2025) show positive Alpha but it drops significantly in the most recent period, and the beta also drops significantly.
*   **Capitalization:** The Company's Market Cap has fluctuated dramatically with the best results from 2018-2020.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 29.28
*   **Previous Close:** 29.81
*   **Change:** -1.78%
*   **5-day SMA:** 30.03
*   **20-day SMA:** 30.73
*   **60-day SMA:** 32.27

**Analysis:**

*   **Downward Trend:** The stock price is currently below all three moving averages (5, 20, and 60-day), suggesting a recent downward trend. The negative change from the previous close reinforces this. The stock price is dipping down.
*   **Relatively stable decline.** The stock price has a gradual decline.

**3. RSI, PPO, and Expected Return**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI:** 29.70 (Oversold)
*   **PPO:** -0.34
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (31 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change (20 days):** -1.9 (Indicates short-term decline)
*   **Expected Return:** -76.1% (Significant underperformance expected compared to S&P 500 over 2 years)

**Analysis:**

*   **Oversold, but Negative Outlook:** The RSI indicates the stock may be oversold and could be due for a bounce. However, the low PPO and very negative expected return paint a bearish picture for the long term. The Hybrid Signal is buying based on the Market Risk Indicator, but it also has a very high MRI rating of 0.9.
*   **Divergence Reinforces Downtrend:** The negative change in relative divergence further reinforces the short-term downward trend.
*   **Contradictory Signals:** The MRI is in the "Medium Investment" range, whereas the expected return is very negative. This highlights the risk and uncertainty associated with the stock.

**4. Recent News & Significant Events**

*   **Mixed Sentiment:** The news headlines present a mixed bag. Some articles discuss the potential for continued gains ("Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains"), while others highlight weaknesses and potential risks ("Earnings Caveat That Sent This Hot Biotech Diving").
*   **Options Activity:** "Is the Options Market Predicting a Spike?" suggests potential for volatility and disagreement among investors.
*   **Fundamental Strength Questioned:** "TG Therapeutics Stock Has Shown Weakness Lately But Financials Look Strong" suggests a disconnect between stock price performance and underlying fundamentals, with the article questioning whether the financials are truly as strong as they appear.
*   **Wall Street Concerns:** "TG Therapeutics: What Wall Street Isn't Telling You" - Seeking Alpha can provide additional insights to the company's performance.

**4-2) Analyst Opinions**

*   **Consensus:** No strong buy/sell signals.
*   **Target Price:** Average target of $44.29, with a wide range ($13.00 - $60.00) indicating significant uncertainty among analysts.
*   **Recent Rating Changes:** No recent rating changes provided.

**Analysis:**

*   **Uncertainty:** The wide range in target prices reflects the high degree of uncertainty surrounding TGTX's future prospects. The lack of recent rating changes makes it difficult to assess current analyst sentiment.
*   **Upside Potential:** The average target price is significantly higher than the current price, suggesting potential upside if the company can meet expectations. However, the low target price warns of downside risk.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|-------------|
| 2025-11-05 | 2.69 | 0.16 B$    |
| 2025-08-08 | 0.19 | 0.14 B$    |
| 2025-05-09 | 0.03 | 0.12 B$    |
| 2024-11-07 | 0.03 | 0.08 B$    |
| 2025-11-05 | 0.03 | 0.08 B$    |

**Analysis:**

*   **Dramatic Improvement:** EPS and Revenue have improved greatly, especially the latest EPS.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.16B  | 82.63%       |
| 2025-06-30   | $0.14B  | 86.58%       |
| 2025-03-31   | $0.12B  | 87.14%       |
| 2024-12-31   | $0.11B  | 85.77%       |
| 2024-09-30   | $0.08B  | 88.86%       |

**Capital and Profitability:**

| Quarter      | Equity  | ROE   |
|--------------|---------|-------|
| 2025-09-30   | $0.61B  | 64.37%|
| 2025-06-30   | $0.28B  | 10.20%|
| 2025-03-31   | $0.24B  | 2.13% |
| 2024-12-31   | $0.22B  | 10.49%|
| 2024-09-30   | $0.19B  | 2.02% |

**Analysis:**

*   **Strong Revenue Growth:** Revenue has been consistently increasing over the past several quarters.
*   **High Profit Margins:** The company boasts very high profit margins, suggesting strong operational efficiency or pricing power.
*   **Equity Growth and ROE Spike:** Equity has increased significantly, particularly in the latest quarter. The ROE (Return on Equity) shows a dramatic spike in the most recent quarter, indicating a highly profitable use of shareholder equity during that period.

**7. Comprehensive Analysis (Summary)**

TGTX is a high-risk, high-reward stock.

*   **Recent performance has been weak compared to the S&P 500.**
*   **The stock is currently in a short-term downtrend and considered oversold, but longer-term expectations are negative.**
*   **Analyst sentiment is uncertain with a wide range of target prices.**
*   **Recent financial performance shows a significant improvement in revenue, profit margins, and ROE.**
*   **The news headlines show mixed sentiments.**

**Overall Assessment:**

The data suggests that TGTX presents a speculative investment opportunity. Recent financials show significant improvements, but this is offset by negative price action, negative sentiment, and long-term underperformance expectations. A turnaround is possible, but the risk is very high.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.